Pages that link to "Q36566561"
Jump to navigation
Jump to search
The following pages link to Eradication of large solid tumors in mice with an immunotoxin directed against tumor vasculature (Q36566561):
Displaying 50 items.
- Improving the efficacy of antibody-based cancer therapies (Q28208361) (← links)
- Antibody drug-conjugates targeting the tumor vasculature: Current and future developments (Q28270261) (← links)
- Vascular targeting: recent advances and therapeutic perspectives (Q33236984) (← links)
- A novel method of differential gene expression analysis using multiple cDNA libraries applied to the identification of tumour endothelial genes (Q33327177) (← links)
- The rationale and future potential of angiogenesis inhibitors in neoplasia (Q33706710) (← links)
- Immunoliposomes for the targeted delivery of antitumor drugs (Q33933508) (← links)
- Antitumor activity of cytotoxic T lymphocytes engineered to target vascular endothelial growth factor receptors (Q34068188) (← links)
- Delivery of lipoplexes for genotherapy of solid tumours: role of vascular endothelial cells (Q34143913) (← links)
- Monoclonal antibody strategies to block angiogenesis (Q34258670) (← links)
- Drug targeting to choroidal neovascularization (Q34416386) (← links)
- Immunotoxins for targeted cancer therapy (Q34646650) (← links)
- Synergy between an antiangiogenic integrin alphav antagonist and an antibody-cytokine fusion protein eradicates spontaneous tumor metastases. (Q34756781) (← links)
- Recent advances in angiogenesis, anti-angiogenesis and vascular targeting (Q35012216) (← links)
- Therapeutic Inhibition of Angiogenesis (Q35550035) (← links)
- Targeting the over-expressed urokinase-type plasminogen activator receptor on glioblastoma multiforme (Q35597943) (← links)
- Hypoxic tumor cell death and modulation of endothelial adhesion molecules in the regression of granulocyte colony-stimulating factor-transduced tumors. (Q35774179) (← links)
- E- vectors: development of novel self-inactivating and self-activating retroviral vectors for safer gene therapy (Q35850215) (← links)
- Psi- vectors: murine leukemia virus-based self-inactivating and self-activating retroviral vectors. (Q35890587) (← links)
- Tumour angiogenesis, vascular biology and enhanced drug delivery (Q35931998) (← links)
- Targeting of stealth liposomes to erbB-2 (Her/2) receptor: in vitro and in vivo studies (Q36141279) (← links)
- Tumour vascular targeting (Q36146905) (← links)
- Review of the effects of anti-angiogenic compounds on the epiphyseal growth plate (Q36421314) (← links)
- Inhibition of angiogenesis and tumour growth by VEGF121-toxin conjugate: differential effect on proliferating endothelial cells (Q36621993) (← links)
- Specific binding of TES-23 antibody to tumour vascular endothelium in mice, rats and human cancer tissue: a novel drug carrier for cancer targeting therapy (Q36641057) (← links)
- Engineering antibodies for imaging and therapy (Q36877861) (← links)
- Antiangiogenic therapy in brain tumors (Q37129915) (← links)
- Immunotherapy against angiogenesis-associated targets: evidence and implications for the treatment of malignant glioma (Q37159509) (← links)
- Radionuclide carriers for targeting of cancer (Q37237705) (← links)
- Tumour vascular disrupting agents: combating treatment resistance (Q37280244) (← links)
- Anticancer strategies involving the vasculature (Q37474318) (← links)
- Radiation-enhanced therapeutic targeting of galectin-1 enriched malignant stroma in triple negative breast cancer (Q37520289) (← links)
- Targeted drug delivery strategies to treat lung metastasis (Q37575499) (← links)
- Targeting cancer vasculature via endoglin/CD105: a novel antibody-based diagnostic and therapeutic strategy in solid tumours (Q37610628) (← links)
- Tumor rim cells: From resistance to vascular targeting agents to complete tumor ablation (Q39205186) (← links)
- Endothelial cells expressing an inflammatory phenotype are lysed by superantigen-targeted cytotoxic T cells. (Q39505993) (← links)
- Identification and angiogenic role of the novel tumor endothelial marker CLEC14A. (Q39517637) (← links)
- Vascular targeting of solid tumours: a major 'inverse' volume-response relationship following combretastatin A-4 phosphate treatment of rat rhabdomyosarcomas (Q39546082) (← links)
- Synergy between vascular targeting agents and antibody-directed therapy (Q39636820) (← links)
- Radioimmunotherapy with astatine-211 using chimeric monoclonal antibody U36 in head and neck squamous cell carcinoma (Q40144418) (← links)
- Tumour vasculature--a potential therapeutic target (Q40403280) (← links)
- Molecular foundations of cancer: New targets for intervention (Q40429882) (← links)
- ZD6126: a novel small molecule vascular targeting agent (Q40686415) (← links)
- Modification of tumor blood flow: current status and future directions (Q40854585) (← links)
- The influence of angiogenesis research on management of patients with breast cancer (Q40930912) (← links)
- Antibody-directed targeting of the vasculature of solid tumors (Q40930942) (← links)
- Breast cancer angiogenesis--new approaches to therapy via antiangiogenesis, hypoxic activated drugs, and vascular targeting (Q40958050) (← links)
- Identification of endothelial cell-surface proteins as targets for diagnosis and treatment of disease (Q40968272) (← links)
- How tumors become angiogenic (Q41100541) (← links)
- Oncogenes as inducers of tumor angiogenesis (Q41121027) (← links)
- Antiangiogenic drugs as a novel anticancer therapeutic strategy. Which are the more promising agents? What are the clinical developments and indications? (Q41711819) (← links)